Tuesday, March 04, 2025 | 08:05 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Gufic Biosciences receives patents for two formulations in India

The company is also in the process of applying patents for the two formulations in other countries

Gufic Biosciences
Premium

Gufic Biosciences

BS B2B Bureau Mumbai
Gufic Biosciences has received patents from the Intellectual Property India, The Patent Office, Government of India, for two formulations - parental formulation of anidulafungin and a freeze dried parental composition of tigecycline.

Anidulafungin is a semisynthetic echinocandin used as an antifungal drug. On the other hand, tigecycline, a glycylcycline that is administered intravenously, is an antibiotic used to treat a number of bacterial infections.

The company said that it was in the process of applying patents for the two formulations in other countries as well.

Gufic Group manufactures pharmaceutical and herbal products along with a wide range of APIs. It is one of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in